Dimension Capital Management’s AbbVie ABBV Stock Holding History

Dimension Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,224	Closed	-$223K	–	106
2024 Q1	$223K	Buy	+1,224	New	+$211K	0.04%	100

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Dimension Capital Management's ABBV Position: Q2 2024 in Review

Dimension Capital Management sold out of AbbVie (ABBV) in Q2 2024, closing a stake of 1,224 shares — an estimated $223K sold.

Dimension Capital Management first reported a position in ABBV in Q1 2024 and held it in 1 quarter. The position peaked at $223K in Q1 2024. 3,364 funds tracked by Wall St. Rank hold ABBV as of Q2 2024.

Dimension Capital Management reported no remaining AbbVie position as of Q2 2024 after selling out during the quarter.
Dimension Capital Management sold 1,224 AbbVie shares in Q2 2024, an estimated $223K.
Dimension Capital Management first reported a position in AbbVie in Q1 2024 and held it in 1 quarter.
Dimension Capital Management's AbbVie position peaked at $223K in Q1 2024.
3,364 funds tracked by Wall St. Rank held AbbVie as of Q2 2024.

Based on Dimension Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.